Oncternal Therapeutics (ONCT) Competitors $1.14 -0.02 (-1.72%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ONCT vs. AIM, SNSE, NLSP, PMCB, WENA, AWH, NKGN, EGRX, JAGX, and TLPHShould you be buying Oncternal Therapeutics stock or one of its competitors? The main competitors of Oncternal Therapeutics include AIM ImmunoTech (AIM), Sensei Biotherapeutics (SNSE), NLS Pharmaceutics (NLSP), PharmaCyte Biotech (PMCB), ANEW Medical (WENA), Aspira Women's Health (AWH), NKGen Biotech (NKGN), Eagle Pharmaceuticals (EGRX), Jaguar Health (JAGX), and Talphera (TLPH). These companies are all part of the "pharmaceutical products" industry. Oncternal Therapeutics vs. AIM ImmunoTech Sensei Biotherapeutics NLS Pharmaceutics PharmaCyte Biotech ANEW Medical Aspira Women's Health NKGen Biotech Eagle Pharmaceuticals Jaguar Health Talphera AIM ImmunoTech (NYSE:AIM) and Oncternal Therapeutics (NASDAQ:ONCT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, community ranking, dividends, media sentiment, valuation, analyst recommendations and profitability. Do institutionals & insiders hold more shares of AIM or ONCT? 12.0% of AIM ImmunoTech shares are owned by institutional investors. Comparatively, 16.0% of Oncternal Therapeutics shares are owned by institutional investors. 0.0% of AIM ImmunoTech shares are owned by company insiders. Comparatively, 11.2% of Oncternal Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor AIM or ONCT? In the previous week, AIM ImmunoTech had 4 more articles in the media than Oncternal Therapeutics. MarketBeat recorded 8 mentions for AIM ImmunoTech and 4 mentions for Oncternal Therapeutics. AIM ImmunoTech's average media sentiment score of 0.60 beat Oncternal Therapeutics' score of 0.00 indicating that AIM ImmunoTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AIM ImmunoTech 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncternal Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, AIM or ONCT? AIM ImmunoTech has higher earnings, but lower revenue than Oncternal Therapeutics. AIM ImmunoTech is trading at a lower price-to-earnings ratio than Oncternal Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAIM ImmunoTech$200K66.93-$28.96M-$0.47-0.45Oncternal Therapeutics$790K4.27-$39.48M-$11.69-0.10 Do analysts recommend AIM or ONCT? AIM ImmunoTech presently has a consensus price target of $3.00, indicating a potential upside of 1,327.89%. Oncternal Therapeutics has a consensus price target of $20.00, indicating a potential upside of 1,654.39%. Given Oncternal Therapeutics' higher possible upside, analysts plainly believe Oncternal Therapeutics is more favorable than AIM ImmunoTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AIM ImmunoTech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Oncternal Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Is AIM or ONCT more profitable? Oncternal Therapeutics has a net margin of -1,599.95% compared to AIM ImmunoTech's net margin of -12,594.21%. Oncternal Therapeutics' return on equity of -177.58% beat AIM ImmunoTech's return on equity.Company Net Margins Return on Equity Return on Assets AIM ImmunoTech-12,594.21% -421.73% -147.54% Oncternal Therapeutics -1,599.95%-177.58%-131.30% Which has more risk & volatility, AIM or ONCT? AIM ImmunoTech has a beta of -0.36, indicating that its share price is 136% less volatile than the S&P 500. Comparatively, Oncternal Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Does the MarketBeat Community believe in AIM or ONCT? AIM ImmunoTech received 26 more outperform votes than Oncternal Therapeutics when rated by MarketBeat users. Likewise, 82.86% of users gave AIM ImmunoTech an outperform vote while only 26.45% of users gave Oncternal Therapeutics an outperform vote. CompanyUnderperformOutperformAIM ImmunoTechOutperform Votes5882.86% Underperform Votes1217.14%Oncternal TherapeuticsOutperform Votes3226.45% Underperform Votes8973.55% SummaryAIM ImmunoTech and Oncternal Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Ad Wide Moat ResearchFormer Trump advisor releases terrifying warningGoldman Sachs: 300 Million People Are At Risk The mainstream media are practically ignoring the most important financial story of the decade. Goldman Sachs, the IMF, JP Morgan, Bank of America, and Morgan Stanley have issued warnings. Yet most ordinary Americans have no idea. Now one former Trump advisor is sounding the alarm. “If people knew the full facts, there’d be blood in the streets.” Get the facts and learn how to protect your family now. Get Oncternal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCT vs. The Competition Export to ExcelMetricOncternal TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.37M$6.57B$5.21B$8.84BDividend YieldN/A8.14%5.53%4.08%P/E Ratio-0.1011.12100.3917.88Price / Sales4.27356.531,229.0485.62Price / CashN/A53.8241.2636.92Price / Book0.3710.597.216.54Net Income-$39.48M$153.02M$119.72M$226.15M7 Day PerformanceN/A3.96%2.13%3.77%1 Month Performance-23.49%-6.72%-2.24%4.46%1 Year Performance-84.80%30.92%32.44%27.57% Oncternal Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCTOncternal Therapeutics1.924 of 5 stars$1.14-1.7%$20.00+1,654.4%-82.5%$3.37M$790,000.00-0.1030Analyst ForecastGap DownAIMAIM ImmunoTech1.9603 of 5 stars$0.21flat$3.00+1,327.9%-50.6%$13.39M$200,000.00-0.4520News CoverageSNSESensei Biotherapeutics4.8191 of 5 stars$0.52+8.3%$4.33+731.6%-20.6%$13.11MN/A-0.4440Gap DownNLSPNLS Pharmaceutics0.7129 of 5 stars$3.43+1.8%N/A+736.6%$13.09MN/A0.006PMCBPharmaCyte Biotech0.6443 of 5 stars$1.70-2.9%N/A-23.1%$13.06MN/A2.582Gap UpWENAANEW MedicalN/A$0.73-0.5%N/AN/A$12.51MN/A0.00N/AGap UpAWHAspira Women's Health1.4316 of 5 stars$0.75flat$4.40+486.7%-76.4%$12.50M$8.96M-0.62110Analyst ForecastGap DownNKGNNKGen BiotechN/A$0.35+2.9%N/A-87.7%$12.38M$80,000.00-0.07N/AEGRXEagle Pharmaceuticals1.0923 of 5 stars$0.95+5.6%N/A-89.4%$12.34M$316.61M0.00134Analyst ForecastGap UpJAGXJaguar Health0.6655 of 5 stars$1.04+6.1%N/A-94.9%$12.27M$9.76M0.0050News CoverageTLPHTalphera2.2557 of 5 stars$0.70flat$4.50+547.4%N/A$11.84M$650,000.000.0019Positive NewsGap Down Related Companies and Tools Related Companies AIM Alternatives SNSE Alternatives NLSP Alternatives PMCB Alternatives WENA Alternatives AWH Alternatives NKGN Alternatives EGRX Alternatives JAGX Alternatives TLPH Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ONCT) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredThe #1 ETF for monthly incomeWe just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncternal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ONCT Stock Alerts